Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study

BACKGROUND/AIMS: Decreased trough levels of infliximab (TLI) and antibodies to infliximab (ATI) are associated with loss of response (LOR) in Crohn's disease. Two prospective studies were conducted to determine whether TLI or ATI better correlates with LOR (Study 1), and whether TLI could becom...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Intest Res
Hlavní autoři: Koga, Akihiro, Matsui, Toshiyuki, Takatsu, Noritaka, Takada, Yasumichi, Kishi, Masahiro, Yano, Yutaka, Beppu, Takahiro, Ono, Yoichiro, Ninomiya, Kazeo, Hirai, Fumihito, Nagahama, Takashi, Hisabe, Takashi, Takaki, Yasuhiro, Yao, Kenshi, Imaeda, Hirotsugu, Andoh, Akira
Médium: Artigo
Jazyk:Inglês
Vydáno: Korean Association for the Study of Intestinal Diseases 2018
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5934595/
https://ncbi.nlm.nih.gov/pubmed/29743835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2018.16.2.223
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky